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ABSTRACT 
This Note addresses the issues related to fertility preservation treatments for cancer 
patients in the context of insurance coverage. As cancer survival rates improve, the 
ability to bear children after therapy is increasingly difficult and a concern for most 
patients. Currently, no states have laws requiring insurance coverage for fertility 
preservation treatments for cancer patients. Because it is not currently covered by 
either private or public insurance, only those who can pay for it on their own can use 
fertility preservation treatments. This Note proposes that Massachusetts, as having 
one of the most inclusive infertility health insurance mandates, should expand 
insurance coverage to those who may become infertile because of cancer treatments. 
Such an expansion would ensure that cancer patients can receive fertility 
preservation treatment prior to commencing chemotherapy or radiation. This Note 
argues that insurance coverage should be extended because it improves a cancer 
patient’s quality of life, and will promote consistency, fairness, and equality. Further, 
this Note explores the constitutional implications of oncofertility. 
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I. INTRODUCTION 
“The prospect of making it through cancer and then not 
having children to share that with seemed a bit like a 
death—a cut-off from the future.” Maria, 28, Ovarian 
Cancer1 
t twenty-eight years old, Maria Arruda found out that cancer took 
her ability to have children too. After battling three years of 
aggressive ovarian cancer, Maria felt a sense of defeat; something 
treasured had been irretrievably lost, and there was nothing to be done 
about it. Prior to chemotherapy, her doctor informed her that she could 
undergo fertility preservation and freeze her eggs. Maria’s health 
insurance coverage was small and Massachusetts did not even consider 
covering medical costs for someone like her. On March 16, 2003, she 
found out she could not have children. Her husband could not look at 
her. She felt inside her somewhere, adjacent to or below the ailing 
heart, a hungry, thirsty, empty, sore, haunted sensation of being 
unfinished, random, and unattached, as if, even if the body were 
working perfectly, there was nothing there for it to run. 
She found herself looking forward to the night time. Sleep came 
down so fast it was only in dreaming that she felt the peculiar new 
thing: motherly. She imagined a daughter, having her lips, nose, and 
chin, caressing each part of her as if she were a rose that a gardener 
paused to admire. Her skin was soft and bright. Her hair was blonde 
and curly, just like her mother’s. That little girl was part of her flesh—
flesh that wept, laughed, and danced on bare feet in the grass. Her 
child, in reality, had no face, no form, no voice, and no odor. She was 
a simple presence in her mind, an all-embracing tenderness with 
strength and a promise of rest. 
Cancer patients like Maria are more commonplace today than ever 
before. Clinical infertility—the failure to conceive after a year of 
trying—is particularly common among adults who receive pelvis 
radiation and a class of chemotherapy drugs called alkylating agents.2 
Over the years, advances in radiation and chemotherapy have 
improved survival rates, but have significantly impacted the 
                                                            
1 Telephone interview with Maria Arruda (October 6, 2013) (on file with author). 
2 Anahad O’Connor, After Cancer, Fertility is Often Within Reach, THE CENTER 
FOR ADVANCED REPRODUCTIVE SERVICES (Mar. 27, 2014, 3:22PM), 
http://fertilitycenter-uconn.org/after-cancer-fertility-is-often-within-reach/. 
A 
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reproductive capability of cancer survivors.3 Certain cancer treatments 
induce infertility rates of eighty percent or more, and some treatments 
estimate that up to ninety percent of cancer patients in their 
reproductive years will be rendered infertile from treatment. 4 
However, no states currently have laws providing for insurance 
coverage for fertility preservation treatments for patients that had 
cancer.5As a result, many patients are unable to have biologically 
natural children after surviving the aggressive disease. 
This Note argues that Massachusetts, as the leading state with the 
most inclusive infertility coverage,6 should provide insurance coverage 
for fertility preservation treatments for cancer patients about to receive 
chemotherapy and radiation. Part II of this Note discusses cancer’s 
unfortunate consequences on a patient’s reproductive system and their 
options for treatment. Part III surveys the different issues regarding 
insurance coverage for cancer patient fertility preservation treatment. 
Lastly, Part IV discusses the current infertility law in Massachusetts 
and suggests that Massachusetts should amend its current mandate by 
adding a clause to cover people facing infertility due to cancer 
treatment. 
II. THE FIGHT TO SAVE TWO LIVES 
“I was shocked. Then devastated. Never warned or 
prepared about this possibility until after it happened. I 
think the infertility was worse than the cancer.” 
Marcia, 27, Ovarian Cancer7 
A. The Emerging World of Oncofertility 
Survival rates among young cancer patients have steadily increased 
each year over the past four decades because of the development of 
                                                            
3 Seema Mohapatra, Oncofertility and Reproductive Justice, HARV. J. ON RACIAL 
& ETHNIC JUST. (forthcoming 2014) (manuscript at 4) (on file with author). 
4 Daniel Basco et al., Insuring Against Infertility: Expanding State Infertility 
Mandates to Include Fertility Preservation Technology for Cancer Patients, 38 
J.L. MED. & ETHICS 832, 836 (2010). 
5 Mohapatra, supra note 3 (manuscript at 1). 
6 Basco, supra note 4, at 832. 
7 Marcia, Survivor Stories, FERTILE HOPE (Mar. 26, 2010), http://www.
fertilehope.org/find-support/cancer-survivor-stories-details.cfm?SID=641. 
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effective cancer treatments.8 Increased survival is due to factors such 
as earlier detection of disease, intensive radiation therapy, and new 
chemotherapies. 9  Data collected by the National Cancer Institute 
(“NCI”) reveals that there are 630,000 young survivors of cancer, and 
that number is increasing each year.10 Twenty five percent of breast 
cancer patients are younger than fourty years old, and over 12,400 
adolescents under nineteen are diagnosed with cancer each year with a 
cure rate of seventy-five percent. 11  Further, survival rates for 
childhood cancer have increased from twenty percent to eighty-one 
percent over the last forty years.12 Ultimately, as the NCI reports, one 
out of every 250 adults will be a survivor of childhood cancer by 
2015.13 This increased rate of survival among cancer patients is largely 
attributable to the tremendous rise in cancer curing drugs. However, 
one of the main complications of these cancer-curing drugs—
particularly for young men, women, and children—is the impact on 
future fertility.14 
“Oncofertility” is a new discipline that bridges the gap between 
oncogology and new medicine in order to discover and apply new 
fertility preservation options for young patients with cancer.15 Under 
the emerging field of oncofertility, medical researchers are 
                                                            
8 The Oncofertility Consortium, About the Oncofertility Consortium, 
NORTHWESTERN UNIVERSITY, http://oncofertility.northwestern.edu/about-us 
(last visited December 15, 2013 ). 
9 Teresa K. Woodruff, The Emergence of a New Interdiscipline: Oncofertility, in 
ONCOFERTILITY: FERTILITY PRESERVATION FOR CANCER SURVIVORS 3, 3 
(Teresa K. Woodruff & Karrie Ann Snyder eds., Springer 2007). 
10 Id. at 4. 
11 Id. 
12 NAT’L CANCER INST., SEER CANCER STATISTICS REVIEW 1975–2005, at 31 
tbl.I-3 (2008), available at http://seer.cancer.gov/archive/csr/1975_2005/results
_merged/sect_01_overview.pdf. 
13 Woodruff, supra note 9, at 4. 
14 See id. at 3. 
15 The Oncofertility Consortium, About the Oncofertility Consortium, 
NORTHWESTERN UNIVERSITY, http://oncofertility.northwestern.edu/about-us 
(last visited Mar. 27, 2014). Dr. Woodruff, the Professor of Obstetrics and 
Gynecology at Northwestern University, coined the term “oncofertility” in 2006 
to incorporate life-after-cancer care with treating the disease. The goal of 
oncofertility is to meet an emerging urgent unmet need for young cancer 
patients: balancing life-preserving treatments with fertility-preserving options. 
Id. 
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investigating new approaches to preserve a cancer patient’s 
reproductive options.16 
In addition, oncofertility strives to close not only the gap between 
oncology and new medicine, but also the wide information gap that 
exists in today’s society.17 This information gap consists of the lack of 
understanding that cancer patients have regarding the possibility of 
infertility resulting from their cancer treatment.18  Ultimately, many 
doctors and oncologists focus on saving the patient’s life rather than 
discussing the future possibility of infertility.19 However, oncofertility 
stresses the importance of oncology providers to facilitate discussions 
about fertility preservation and post-cancer quality of life. 20  It is 
critical for clinicians to educate patients on their options for fertility 
preservation early in the process for cancer risk management. 
B. Infertility: Casualty of Cancer Treatment 
Decreased fertility after cancer treatment is mainly caused by the 
exposure to radiation and the alkylating agent chemotherapy. 21 
Infertility is an unfortunate and likely result for many cancer patients, 
with certain cancer treatments inducing infertility rates of eighty 
percent or more.22 Some treatments estimate that up to ninety percent 
of cancer patients in their reproductive years will be rendered infertile 
from treatment.23 Rates of infertility vary according to cancer site, type 
of treatment, and the age of a patient.24 
There are many different fertility preservation options available to 
newly diagnosed cancer patients. First, there are traditional options, 
which include adoption and third-party reproduction. 25  Second, 
                                                            
16 See Gregory Dolin, Medical Hope, Legal Pitfalls: Potential Legal Issues in the 
Emerging Field of Oncofertility, 49 SANTA CLARA L. REV. 673, 674 (2009). 
17 See Brigid K. Martz, Learning to Bridge the Information Gap, THE 





21 Dolin, supra note 16, at 673. 
22 Basco, supra note 4, at 836. 
23 Id. 
24 G.P. Quinn et al., Frozen Hope: Fertility Preservation for Women with Cancer, 
55 J. MIDWIFERY & WOMEN’S HEALTH 175, 175 (2010). 
25 Third-party reproduction consists of gamete donation and/or uterine surrogacy 
for cancer patients whose therapies diminished these functions. Dolin, supra 
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assisted reproductive technology provides new and advanced ways to 
preserve fertility.26 Technology is significantly advancing in the area 
of fertility preservation after cancer treatment.27 
In men, cancer itself may be correlated with low sperm counts.28 
However, the primary threat for male cancer patients is a compromised 
sperm production, quality, motility, and DNA damage caused by 
exposure to chemotherapy and/or radiation.29 The most proven and 
successful method of fertility preservation for men is semen 
cryopreservation, where patients provide semen samples which are 
frozen for later use.30  Intrauterine insemination or intracytoplasmic 
sperm injection is extremely effective, as one single sperm may be 
sufficient to result in a pregnancy.31 The primary concern for male 
cancer patients is to reach a sperm bank in a timely manner, as sperm 
represent a ready and available source in large numbers and can be 
cryopreserved easily.32 
In women, cancer treatments pose a variety of reproductive risks 
including immediate infertility, premature menopause, and 
compromised ability to carry a pregnancy due to uterine or cervical 
damage. 33  Women who undergo chemotherapy or radiation during 
their reproductive years have a forty to eighty percent chance of losing 
fertility.34 Chemotherapy and radiation can damage or destroy oocytes 
                                                                                                                                            
note 16, at 683. These options are valuable means of forming a family, but do 
not fulfill a woman’s or man’s desire to have biological children. See id. at 684. 
26 See Dolin, supra note 16, at 684. 
27 See Ina N. Cholst, Oncofertility: Preservation of Reproductive Potential, 61 
DEPAUL L. REV. 763, 763 (2012). 
28 FERTILE HOPE,CANCER AND FERTILITY: FAST FACTS FOR REPRODUCTIVE 
PROFESSIONALS 5 (2008), available at http://www.fertilehope.org/uploads/pdf
/FH_RP_FastFacts_08.pdf. 
29 Id. 
30 See Dolin supra note 16, at 684. If the male cancer patient cannot obtain a 
semen sample by ejaculatory methods because of the nature of his condition, a 
surgical biopsy can be performed and mature sperm may be extracted. Id. 
31 See id. 
32 Id. 
33 FERTILE HOPE, CANCER AND FERTILITY: FAST FACTS FOR ONCOLOGY 
PROFESSIONALS 6 (2008) http://www.fertilehope.org/uploads/pdf/08_FH_Onc_
FastFacts.pdf [hereinafter CANCER AND FERTILITY: FAST FACTS]. 
34 Quinn, supra note 24, at 175. Infertility rates vary depending on many factors; 
including cancer site, type of treatment, and the patient’s age. Infertility in 
cancer patients can be caused by the cancer or the type of cancer treatment that 
is involved. Exact infertility rates are not known because no valid measures exist 
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and follicles, which can cause either immediate or premature 
menopause years after treatment. 35  In addition, surgery to remove 
reproductive organs such as the ovaries, fallopian tubes, uterus, and 
cervix will reduce a woman’s ability to become pregnant or carry a 
child.36 In addition, radiation can damage the uterus and increase the 
risk of miscarriage or low-birth weight.37 
A number of treatments are available for infertility for women but 
are more limited than those available to men.38 The most common 
fertility preservation procedure is in vitro fertilization (“IVF”).39 There 
are also experimental options available such as in vitro maturation or 
ovarian tissue freezing. 40  The most well-established treatment, 
however, is to undergo ovarian stimulation for maturation and retrieval 
of the eggs.41 The oocytes are fertilized on the day of egg retrieval and 
                                                                                                                                            
for women to establish that fertility was present prior to treatment. However, 
women who undergo chemotherapy or radiation during their reproductive years 
have a forty to eighty percent chance of losing fertility. Treatments using the 
alkylating agents of cyclophosphamide, methotrexate, and fluorouracil produce 
the greatest risk for infertility. Further, total body radiation and external beam 
radiation also produces great risks for infertility. Id. 
35 CANCER AND FERTILITY: FAST FACTS, supra note 33, at 6. 
36 Id. 
37 Id. 
38 Dolin, supra note 16, at 684. Many techniques that are used, including embryo 
and oocyte cryopreservation, require hormonal stimulation, which is problematic 
and thus poses many limitations. Cancer treatment must be delayed when 
undergoing stimulation procedures, but it is imperative that a patient begin 
treatment immediately after cancer diagnosis. In addition, ovarian stimulation 
may elicit reactions from hormonally responsive cancers, such as breast and 
ovarian cancers. See id. at 685. 
39 CANCER AND FERTILITY: FAST FACTS, supra note 33, at 12. With IVF, doctors 
retrieve eggs from a woman’s ovary after hormonal stimulation of the ovaries, 
fertilize the eggs with sperm in a petri dish, and transfer some of the embryos to 
the woman’s uterus. The remaining embryos are frozen for future use. See David 
Orenlicher, Discrimination Out of Dismissiveness: The Example of Intfertility, 
85 IND. L.J. 143. 154. 
40 In vitro maturation involves removing immature oocytes and then maturing 
them in vitro. CANCER AND FERTILITY: FAST FACTS, supra note 33, at 12. Once 
matured, the oocytes can either be frozen or fertilized to create embryos and 
then frozen. Ovarian tissue freezing involves the removal, sectioning and 
freezing of an ovary. The ovarian strips can be transplanted later to restore 
hormonal function and for use with IVF. Id. 
41 Sanjay K. Agarwal & R. Jeffrey Chang, Fertility Management for Women with 
Cancer, in ONCOFERTILITY: FERTILITY PRESERVATION FOR CANCER SURVIVORS, 
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the resultant embryos are cryopreserved.42 The embryos can be thawed 
and transferred into either the patient’s own uterus, providing that her 
uterus is viable for pregnancy, or that of another woman as a 
gestational surrogate. 43  The success rates for these procedures are 
dependent upon the woman’s age at the time the eggs were retrieved 
and fertilized.44 
Traditional infertility patients are often able to receive infertility 
treatment until they are able to conceive, which differs dramatically 
from cancer patients. 45  Cancer patients have only one substantial 
chance at preserving fertility because they are only able to receive 
fertility treatment before they begin cancer treatment.46 Consequently, 
cancer patients typically undergo treatment immediately or shortly 
after their diagnosis, giving them a short period of time to utilize 
fertility preservation treatment. 
C. Insurance Coverage for Fertility Preservation Treatments 
Insurance companies do not typically cover fertility preservation 
treatments because they are commonly viewed as elective procedures 
rather than medically necessary.47 Infertility resulting from radiation or 
chemotherapy is typically known as an iatrogenic condition. 48 
Insurance companies generally cover treatment for iatrogenic 
conditions that result from cancer treatment, even though they do not 
                                                                                                                                            
at 6 (2007), http://oncofertility.northwestern.edu/sites/default/files/uploadedfile
content/onco_chapter_2.pdf. 
42 Id. at 6. 
43 Id. 
44 Id. at 7. 
45 Basco, supra note 4, at 834. 
46 Id. 
47 Lisa Campo-Englestein, Insurance Coverage for Cancer Treatment Induced 
Conditions: Comparing Fertility Preservation to Breast Reconstructive Surgery, 
61 DEPAUL L. REV. 849, 854 (2012). 
48 Id. at 854.An iatrogenic condition is a negative side effect or adverse condition 
that is caused by the diagnosis, manner, activity, or treatment of a healthcare 
provider. Id. Specifically, in relation to cancer, we refer to infertility as a 
nonnegligent iatrogenic condition, which occurs when medically necessary 
treatments have unavoidable or unpredictable negative side effects. For 
example, this may occur when cancer treatment causes infertility, hair loss, or 
nausea in a patient. Id. at 850. 
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cover these same conditions when they are naturally occurring. 49 
However, infertility treatment is typically not covered.50 
Most health-care plans will not reimburse patients or physicians 
for the cost of IVF or other technologies to assist reproduction, and 
even when insurance provides coverage, it typically is inadequate.51 
Twelve states mandate insurance coverage for infertility treatments, 
and two states require that coverage be offered.52 However, it appears 
that no state currently provides insurance coverage specifically for 
fertility preservation treatment for cancer patients. When an insurance 
company denies fertility preservation coverage, there is a minimal 
amount of time to appeal.53 Consequently, cost and lack of insurance 
coverage are major reasons why many female patients do not undergo 
fertility preservation treatment.54 
The costs of fertilization preservation treatments and procedures 
vary.55 The price to receive information and advice about procedures 
                                                            
49 Id. at 851. 
50 Id. 
51 Judith F. Daar, Accessing Reproductive Technologies: Invisible Barriers, 
Indelible Harms, 23 BERKELEY J. GENDER, L.& JUST. 18, 22 (2009). 
52 Id. 
53 Mohapatra, supra note 3 (manuscript at 3); Nat’l Conference of State 
Legislatures, State Laws Related to Insurance Coverage for Infertility Treatment 
(May 2009), http://www.ncsl.org/programs/health/50infert.htm. 
54 A study conducted from January 2011 to October 2012 surveyed reproductive 
aged women with cancer who were being counseled by a reproductive health 
clinic for fertility preservation. Patients completed surveys at four different 
points in time, including before and after a new patient consultation, at the time 
they made a decision about fertility preservation, and six to eight months after 
consultation. The possible reasons for not undergoing fertility preservation 
included: risks to fertility from cancer treatment, cost, lack of insurance 
coverage, age, delay of cancer treatment, and future pregnancy’s effect on long 
term prognosis. Ninety-four women were surveyed, and fifty-two percent of 
women did not undergo FP, ninety percent of which identified cost and lack of 
insurance coverage as the reason for not undergoing treatment. See E.E. 
Niemasik, et. al., It Comes Down to Money: Why Women Decide Not to 
Undergo Fertility Preservation, 98 FERTILITY AND STERILITY S122 (2012); see 
also DEBORA L. SPAR, THE BABY BUSINESS: HOW MONEY, SCIENCE, AND 
POLITICS DRIVE THE COMMERCE OF CONCEPTION 30 (2006) (“In this market, 
therefore, price acts harshly as a constraint on demand. The desire is there, as we 
know. So, increasingly, is the supply. Yet the price of this supply is still too high 
for many potential buyers, leaving supply and demand to meet at a point well 
below their full potential.”). 
55 Elizabeth A. Pendo, The Politics of Infertility: Recognizing Coverage Exclusions 
as Discrimination, 11 CONN. INS. L.J. 293, 300 (2005). 
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typically only cost the amount of a general office visit.56 Further, the 
price of treatment intrauterine insemination is typically only a few 
hundred dollars.57 However, estimates for IVF range from $8,000 to 
$10,000 per procedure, and patients usually must undergo more than 
one procedure during this process.58 Below, in Table 1, is a summary 
of the average prices of the most common fertility preservation 
treatments.59 
 












$6608 $8285 $244 $381 
annually 
 
Many different views exist as to why insurance coverage is not 
extended to cancer patients. First, many of the most effective assisted 
reproductive technologies are deemed experimental and many insurers 
do not cover experimental procedures.60 Further, insurance companies 
typically cover conditions that currently exist or conditions that are 
certain to occur, and infertility is not definite.61 Even after a patient 
undergoes fertility preservation procedures, the embryos, eggs, or 
ovarian tissue may not be used until some later time in the far future.62 
Finally, insurance companies find that fertility preservation is vastly 
complex when compared to other side effects of cancer because it 
affects the patient’s family and future offspring.63 These views will be 





59 Fertility Preservation for Cancer Patients: Demographic Disparities in 
Counseling and Financial Concerns are Barriers to Utilization, AMERICAN 
SOCIETY FOR REPRODUCTIVE MEDICINE (Oct. 23, 2013), http://www.socrei.org
/Fertility_Preservation_for_Cancer_Patients_Demographic_Disparities_in_Coun
seling_and_Financial_Concerns_Are_Barriers_to_Utilization/. 




64 See infra Part IV. 
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Despite the criticism, oncofertility is making its way to the 
insurance sphere. Currently, Connecticut,65  Hawaii,66  New Jersey,67 
and California68 have bills pending that deal with fertility preservation 
insurance coverage specifically for cancer patients. The California 
Bill, in particular, would require a health care service plan and a health 
insurer to provide, on a group and individual basis, coverage for 
medically necessary expenses for standard fertility preservation 
services when a necessary medical treatment may directly or indirectly 
cause iatrogenic infertility.69 Further, the United States Congress also 
has a bill pending for a similar goal.70 The Family Act of 2013 has 
been introduced into both the U.S. Senate and U.S. House of 
Representatives—S 881/HR 1851, respectively—and will provide 
critical financial support for young people with cancer, autoimmune 
disorders, and other conditions whose treatment may save their lives 
yet damage their ability to have children in the future.71 The Family 
Act will create a tax credit for eligible taxpayers to cover fifty percent 
of the cost of IVF and fertility preservation up to the maximum 
amount set by the ATC—$12,970 this calendar year.72 
Further, in June 2013, the American Medical Association (AMA) 
adopted a policy that supports coverage by all insurance providers of 
fertility preservation treatment for cancer patients undergoing 
treatments “that may result in infertility”. 73  The AMA stated that 
                                                            
65 A.B. 5644, Gen. Assembly Reg. Sess. (Conn. 2013). 
66 H.B. 2105, 26th Leg., Reg. Session (Haw. 2012). 
67 A.B. 2479, 215th Leg., 1st Session (N.J.2012). 
68 A.B. 912, Reg. Session (Cal. 2013-2014). 
69 Id. The fiscal effect of Bill AB 912 was found to result in approximately 
$69,000 of additional costs to the California Public Employees’ Retirement 
System for additional premiums and unknown costs, potentially greater than 
$100,000, to the extent the fertility treatment preservation services exceed the 
Essential Health Benefits (EHB) of the Affordable Care Act (ACA). Quirk-
Silva, Bill Analysis for A.B. 912, Reg. Session (Cal. 2013-2014) 1, available at 
http://leginfo.ca.gov/pub/13-14/bill/asm/ab_0901-0950/ab_912_cfa_20130624_
135304_sen_comm.html. 




73 AMA Adopts New Policies on First Day of Voting at Annual Meeting, 
AMERICAN MEDICAL ASSOCIATION (June 17, 2013), http://www.ama-
assn.org/ama/pub/news/news/2013/2013-06-17-new-ama-policies-annual-
meeting.page#. 
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coverage for infertility treatments “should be an essential part of the 
management of [patients] cancer.”74 This policy treats infertility as a 
side-effect of treatment or a negative condition created by cancer.75 
Consequently, it is slowly being recognized that the need for fertility 
preservation treatment is a result of a medical condition and not just a 
desired elective procedure.76 
III. CURRENT LAW: MASSACHUSETTS AND FERTILITY COVERAGE 
“I am saddened that so many people not only have to 
go through cancer and the treatments required just to 
overcome this disease and be able to live, but also have 
to worry about whether or not they will ever become 
parents.” Thomas, 34, Testicular Cancer77 
In 1987, Massachusetts passed the Act Providing a Medical 
Definition of Infertility (“Infertility Act”). 78  RESOLVE, a national 
infertility advocacy group based in Massachusetts, began pushing for 
an insurance mandate.79 This advocacy group wanted infertility to be 
labeled as a medical condition necessitating treatment, removing it 
from the sphere of a cosmetic problem to a medical problem.80 Thus, 
the confluence of interests created a mandate to include insurance 
coverage requirements for infertility services at the same level as 
pregnancy-related services.81 
In Massachusetts, infertility refers to the condition of an individual 
who is unable to conceive or produce conception during a period of 
one year if the female is age 35 or younger or during a period of six 
months if the female is over the age of 35.82 Under the mandate, all 
                                                            
74 Id. 
75 Angela Krausfeldt, Support for Fertility Preservation Now an AMA Policy!, THE 




77 Thomas, Survivor Stories, FERTILE HOPE (March 26, 2010), http://www
.fertilehope.org/find-support/cancer-survivor-stories-details.cfm?SID=626. 
78 See K. Cullen, Law Orders Coverage for Infertility, BOSTON GLOBE, October 9, 
1987. 
79 Basco, supra note 4, at 833. 
80 Id. 
81 Id. 
82 211 C.M.R. § 37.03 (2012). 
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insurers providing pregnancy-related benefits shall provide for the 
diagnosis and treatment of infertility, including the following: artificial 
insemination; IVF; GIFT; sperm, egg, and/or inseminated egg 
procurement and processing; and banking of sperm of inseminated 
eggs, to the extent such costs are not covered by the donor’s insurer.83 
Under the mandate, however, insurers are not required to cover, but 
are not prohibited from recovering, experimental infertility procedures, 
surrogacy, reversal or voluntary sterilization.84 Further, Massachusetts 
insurance companies and HMPs must cover “the medically necessary 
expenses of diagnosis and treatment of infertility.” 85  The statute 
further places limits to the same extent as they are provided for other 
pregnancy-related procedures and—subject to the other terms and 
conditions of the subscription certificate—coverage for medically 
necessary expenses of diagnosis and treatment of infertility.86 
Massachusetts’ infertility mandate is one of the most inclusive 
health insurance mandates regulating coverage for infertility services 
in the United States.87 The Massachusetts mandate creates a review 
system that allows for additional infertility services to be covered as 
medical technology advances and procedures move from experimental 
to routine.88 Unlike other states, Massachusetts’ mandate places few 
limitations on covered procedures.89 However, the mandate still fails 
to include patients who face infertility due to cancer treatment. 
The Affordable Care Act (“ACA”) is unlikely to have a dramatic 
impact on infertility care and does not directly address infertility 
coverage.90 However, the law does give states the power to determine 
the scope of insurance coverage for a variety of medical conditions 
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and procedures, including infertility.91 Consequently, ACA does little 
to standardize the state-mandated insurance policies dealing with the 
diagnosis and treatment of infertility.92 The ACA does require that 
health plans offered in the small group and individual markets cover 
Essential Health Benefits (“EHBs”) effective January 1, 2014, but this 
does not necessarily include infertility treatment.93 As Massachusetts 
currently mandates coverage for infertility treatment, it also included 
the infertility mandate in its Benchmark plan. 94  Thus, in 
Massachusetts, infertility treatment is an essential benefit.95 It might 
therefore be said that, because the ACA does not mandate infertility 
treatment, it does not pose an incredible disadvantage or even make a 
big difference in infertility treatment via insurance coverage.96 
Unfortunately, while extremely inclusive, the mandate primarily 
affects those who have health insurance and who meet the 
Massachusetts definition of infertility. The Massachusetts mandate 
essentially is designed for a “presumably healthy individual.” 97 
Unfortunately, cancer patients are not included under the definition of 
infertility in Massachusetts because cancer patients are not considered 
physiologically or medically infertile at the time when fertility 
preservation treatment would take place.98 Therefore, it is under the 
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exist, rather than being proactive in preventing conditions from 
existing in the future.99 
Under existing state law, a cancer patient is considered part of the 
general population with regard to the class of persons protected by 
laws relating to infertility.This is problematic because cancer survivors 
have characteristics that set them apart from the general population 
intended to be addressed by fertility insurance law.100 The language of 
the law itself attests to the non-applicability of its provisions to cancer 
patients, particularly young, unmarried men and women.101 Therefore, 
cancer survivors would have to wait until they met the clinical 
definition of infertility before attempting to use insurance benefits.102 
This is unlikely because chemotherapy and radiation are prone to 
render a patient without viable sperm or eggs, and the most likely 
chance of success will come from the sperm or eggs harvested before 
the initiation of cancer treatment.103 
IV. SOLUTION: EXTENDING FERTILITY PRESERVATION COVERAGE 
TO CANCER PATIENTS 
“Having breast cancer made me want children even 
more. When you are faced with your own mortality 
each day, you want to make sure you leave some sort of 
legacy behind.” Tonya, 21, Breast Cancer104 
A. Proposed Legislation and Implementation 
Massachusetts should provide insurance coverage for fertility 
preservation procedures for cancer patients about to receive 
chemotherapy and radiation, both of which often cause infertility. 
Treatment to preserve fertility in men and women can be done before 
chemotherapy or radiation and can be used after the patient is free of 
cancer.105 Particularly, Massachusetts should add a clause to its current 
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mandate extending fertility preservation insurance coverage to cancer 
patients. With this legislation, Massachusetts would create a separate 
and different definition of infertility for cancer patients and survivors. 
Thus, although cancer patients would not be able to meet the standard 
definition of infertility, they would be able to meet the separate 
definition of infertility set out in the amended mandate. The added 
clause may look as follows, as modeled by the California Bill A.B. 
912106: 
(1) Every group or individual health care service plan that is 
issued, amended, or renewed on and after January 1, 2016, that 
provides hospital, medical, or surgical coverage shall include 
coverage for medically necessary expenses for standard fertility 
preservation services when a necessary medical treatment may 
directly or indirectly cause iatrogenic infertility to an enrollee. 
(2) For purposes of this section, the following terms have the 
following meanings: 
(a) “Standard fertility preservation services” means 
procedures consistent with established medical practices 
and professional guidelines published by the American 
Society of Reproductive Medicine, the American Society 
of Clinical Oncology, or other reputable professional 
organizations. 
(b) “May directly or indirectly cause” means treatment 
with a likely side effect of infertility as established by the 
American Society for Reproductive Medicine, the 
American Society of Clinical Oncology, or other 
reputable professional organizations. 
The current Massachusetts mandate gives the Massachusetts 
Commissioner of Insurance the authority to establish a list of required 
and optional infertility benefits, along with the authority to oversee the 
process of adding new procedures to what would be covered.107 In 
order for a new procedure to be added, an individual must petition the 
commissioner to recognize the procedure as fundamental or non-
experimental.108 This process has allowed for the mandate to evolve as 
medical technology advances without the need for further legislative 
steps.109 
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With the increase in survival rates and decrease in fertility due to 
new and advanced cancer-curing drugs, the commissioner may amend 
the existing mandate, as modeled above, to include cancer patients. 
The mandate would ultimately provide separate standards for cancer 
patients to meet the definition of infertility. This is an extremely 
beneficial and workable option, as it recognizes that cancer patients 
have limited time to preserve their fertility before beginning treatment 
that is likely going to render them infertile. Massachusetts should 
implement this flexible policy with the insurance mandate so that the 
mandate will evolve as technology advances. Thus, with medical 
technology and advances in cancer survival, it is plausible for 
Massachusetts to take this route and extend coverage for cancer 
patients in this way. 
Further, health insurance mandates have become extremely 
popular in the United States, especially those specifically centered on 
cancer. 110  From 2000 to 2003, an average of seventy six health 
insurance mandates were passed per year, which rose from fifty nine 
mandates per year during the 1990s.111 Every state now has at least 
one health insurance mandate applying to cancer.112 For example, all 
states now have legislation regulating coverage for breast 
reconstructive surgery after surviving breast cancer and many states 
also address coverage for diagnosing prostate cancer.113 As mandates 
are becoming more common place, it may be reasonable to predict that 
an addition to a mandate will be passed for cancer patients to receive 
infertility treatment insurance coverage. 
B. Why Should Coverage Be Extended? 
In one study of cancer survivors, seventy-six percent of those who 
were childless expressed a desire to have biological children in the 
future. 114  Most fertility preservation treatments and procedures for 
cancer patients are not covered by insurance, even in Massachusetts 
which has mandated IVF coverage. Those who are unable to have 
children because of certain cancer treatments thus must pay out of 
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pocket for further treatment for infertility. As discussed more below, 
this section suggests that coverage for infertility preservation should 
be expanded to cancer survivors due to the issues of quality of life, 
fairness, consistency, equality, and certain constitutional 
considerations. 
1. Quality of Life 
The inability to reproduce, although not life-threatening or 
harmful, adversely affects a person’s quality of life tremendously. Men 
and women typically do not expect to be infertile, and news of 
infertility comes as a severe shock. 115  Consequently, infertility is 
extremely emotionally distressing. Psychological responses to 
infertility range from surprise, denial, anxiety, anger, guilt, low self-
esteem, isolation, hopelessness, feelings of unfulfillment, social 
withdrawal, and depression.116 Those who experience infertility also 
experience changes to their perceptions of their lives. This can include 
feelings of an inability to plan the future, the inability to find meaning 
in life, and the overgeneralization of loss of control over reproduction 
to other aspects of life.117 
Many studies have found that infertility patients also find infertility 
to be one of the most upsetting experiences of their lives.118 In addition 
to a cancer diagnosis, many people deal with infertility as they would a 
loss of a loved one.119 Infertility brings not only the loss of the ability 
to have children, but the loss of pregnancy, childbirth, and 
breastfeeding, and experiences of genetic continuity, parenthood, and 
relationships. 120  Ultimately, cancer patients may also deal with 
subsequent repercussions of infertility that require more extensive 
medical appointments, testing, medication, surgeries, physical pain, 
numerous unfortunate side effects, fear, grief, and psychological 
identity adjustment.121 
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Mandating insurance coverage for fertility preservation thus has 
the power to transform the quality of life for cancer survivors.122 
Without insurance coverage, patients may opt out of fertility 
preservation, which may result in high costs for the survivor years later 
when he or she is trying to build a family and create a life after cancer, 
and further enforce the feelings of anguish and grief that patients’ 
experience.123 If men and women have the option to preserve their 
fertility before undergoing treatment—and have the opportunity to 
afford it—they will not have to deal with these other devastating 
effects of cancer and their quality of life will improve greatly. 
In terms of financial impact, expanding this coverage is only for a 
relatively small number of people during their reproductive years and 
will only minimally impact insurance premiums when spread out 
amongst all insured persons.124 Without such coverage, patients are 
unable to afford this unexpected out-of-pocket expense, especially 
when facing other significant costs surrounding the cancer treatment 
itself.125 A study conducted in 1998 revealed that mandated infertility 
coverage was associated with increased use of assisted reproductive 
technology, but there were no excessive increases in consumer cost for 
infertility insurance coverage.126 While expanding coverage to include 
infertility treatment for cancer patients may increase demand because 
of the lower costs to patients, these increases would be small 
considering the limited number of people who are diagnosed with 
cancer at the heart of their reproductive age.127 For example, one study 
demonstrated that if utilization of IVF rose to a high of three hundred 
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percent as a result of expansion, premiums would only increase about 
nine dollars per employee per year.128 
Further, although nontraditional parenting is becoming more 
prominent in today’s society, the options of adoption and the use of 
donor gametes and surrogacy should not substitute extending 
insurance coverage all together. Cancer survivors face significant 
obstacles when dealing with non-biological parenting options. 129 
Options such as these are costly, and adoption is typically restricted to 
young and healthy married couples. 130  In order to adopt a child, 
agencies frequently require documentation and proof that cancer 
survivors have been disease-free for at least five years. 131  These 
options may provide an individual with the means of forming a family, 
but fail to fulfill the desire of many individuals to making a family. 
Thus, these options do not vastly improve a patient’s quality of life. 
2. Consistency and Fairness 
Health care providers often provide for certain measures to prevent 
iatrogenic conditions from occurring.132 Almost every side effect of 
cancer and its treatment is covered by health insurance except for 
infertility.133 First, insurance covers antiemetics for nausea and dental 
evaluations for osteoradionecrosis.134 Other conditions resulting from 
cancer, such as hair loss, are also covered under insurance.135 Scholars 
have compared infertility treatments to breast reconstruction 
procedures, which are also covered by insurance. 136  Covering 
infertility treatment for cancer patients with iatrogenic infertility 
ultimately creates consistency and fairness in policy coverage, rather 
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than treating infertility differently than other iatrogenic conditions that 
are covered. 
Although insurance companies rarely cover experimental 
procedures, many fertility preservation treatments are no longer 
considered experimental by scientists.137 The freezing of a woman’s 
eggs has become increasingly ordinary, with seventy to ninety percent 
of eggs surviving the process. 138  Further, the technology of egg 
preservation and freezing is improving rapidly.139 Most importantly, 
egg and ovarian tissue cryopreservation are the only options available 
for young or single women to be able to have a child in the future with 
someone without a sperm donor. 140  Fertility preservation options 
should be available for single women to have a biological child in the 
future with the person of their choice. 
Although infertility cannot be calculated to an exact certainty—
like hair loss or the loss of a breast—this should not preclude 
insurance coverage of the condition. For instance, insurance 
companies provide coverage for nausea, although it may not be 
absolutely certain to occur.141 They also cover storing one’s blood as a 
prophylactic precaution in case there needs to be an emergency 
transfusion, which also cannot be predicted. 142  Similarly, patients 
undergoing cancer treatment also may find themselves rendered 
infertile, and thus fertility preservation treatment, like blood storage, 
should be saved in that “just-in-case” scenario. This speaks to 
consistency and fairness, and Massachusetts should set the way for 
insurance to cover iatrogenic infertility. 
Cancer patients are simply not responsible for their infertility, and 
not providing them insurance coverage for a medical implication out 
of their control promotes unfairness. However, for example, it is 
possible, albeit crass, to suggest that a woman who seeks fertility 
preservation treatment to address age-related infertility is responsible 
for her own condition because she intentionally delayed her child-
bearing; yet this is covered by insurance.143 It would be equally absurd 
to suggest that a patient with cancer—who is typically not “causally 
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responsible” for his or her condition 144 —who decides to have 
treatment that could result in infertility should not get insurance 
coverage for his or her condition. Rather, our present system forces a 
cancer patient to ultimately choose between two losses: the loss of life 
or the loss of fertility.145 Because there is no causal responsibility, as it 
is out of a cancer patient’s control, and because insurance companies 
already cover other “possible” side effects, insurance companies 
should extend their own policies and extend coverage. 
3. Equality 
An insurance mandate that is extended to cancer patients can create 
a sense of equality in certain ways. First, anecdotal evidence from 
Massachusetts suggests that because the state recognizes same-sex 
marriages and gives equal insurance benefits regardless of marriage, 
coverage may be expanded to include same-sex couples and could 
expand to unmarried cancer patients.146 Second, equality among men 
and women can be considered when dealing with extending the 
infertility mandate to cancer patients. Fertility preservation treatment 
is a lot cheaper for men than it is typically for women. 147  Thus, 
extending insurance coverage for cancer patients will allow women 
more affordable options for treatment that are closer in price to their 
male counterparts. 
Inequality is not created by extending coverage because those who 
will never need infertility treatments have to pay for them. The 
purpose of health insurance, ultimately, is to pool risks in order to 
provide affordable health care for all members. 148  Those who are 
insured pay into the insurance pool, hoping they will never have to 
utilize it.149 On the contrary, infertile couples or individuals must pay 
for others’ maternity and childbirth expenses that they are unable to 
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4. Constitutional Considerations 
Finally, although the courts have not considered the issue of 
fertility preservation treatment and cancer directly, the rights to 
reproduce and bear children are rooted in American law and should be 
taken into consideration. The Supreme Court has recognized the ability 
to have children as a fundamental right.151 Further, the Supreme Court 
has established that reproduction is a central role in the lives of many 
individuals, and has also labeled reproduction as a major life 
activity. 152  Cases involving the right to use contraceptives further 
demonstrate that the right to make decisions regarding sexual activities 
and reproduction is a substantive due process right, as the Supreme 
Court has protected a married couple’s right to use contraceptives in 
Griswold v. Connecticut.153  Thus, the Court described reproductive 
freedom as “intimate to the degree of being sacred.”154 The Court 
extended the protection beyond married couples to single individuals 
in Eisenstadt v. Baird, holding that the right to privacy encompasses 
the right of a single individual to make his or her own decisions as to 
whether “to bear or beget a child.”155 Taking it even further, in Ohio v. 
Akron Center for Reproductive Health, the Supreme Court extended 
this right to minors.156 
While no state explicitly protects a right to use assisted 
reproductive technology (“ART”) or procedures such as IVF, both 
state and federal governments implicitly acknowledge that such a right 
exists.157 As Massachusetts mandates insurance coverage for IVF, it 
necessarily recognizes the legality of ART to support citizens’ access 
to these services.158  Thus, some courts currently acknowledge that 
procreative liberty encompasses, subject to state and judicial 
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regulation, the right to use ART.159 Not allowing cancer patients to 
undergo fertility preservation treatment under the current mandate 
therefore inhibits their right to reproduction, creating various 
constitutional concerns. Not being able to afford these procedures, a 
patient should therefore argue that this inhibits their substantive due 
process right to make decisions about reproduction. 
5. Further Concerns and Comments 
The area of oncofertility raises a number of moral and ethical 
questions. Among these concerns are the ethical implications of 
removing and freezing embryos; the question of who can consent to a 
procedure; property ownership of the reproductive material; and the 
control of the reproductive tissue if the patient has died.160 Questions 
of financing, religious objections, and access must be considered.161 
The emerging field of oncofertility creates new hope and possibilities 
for individuals whose fertility may be compromised by cancer 
treatment and it is a field that is still growing. The Oncofertility 
Consortium continues to expand their analysis on such legal and 
ethical implications, striving for patients to have the ability to have 
children and to exercise their freedom to make reproductive decisions 
in the most ethical and legal manner.162 
V. CONCLUSION 
“I remember seeing a picture in my breast surgeon’s 
office that has a list of things that cancer cannot do. 
And I wanted that to include that it couldn’t take 
pregnancy away from us. Even if we never use the eggs 
or get pregnant on our own, it would be a blessing. I 
refer to my frozen eggs as my pocket full of sunshine.” 
Michele Foust, 26, Breast Cancer163 
Advances in medicine and technology now allow young cancer 
patients the option of preserving their fertility, and it is important that 
these patients have the monetary tools necessary to do so. The 
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technology exists that allows cancer patients to enter survivorship with 
the option to have a biological child, but is out of reach due to 
extensive costs.164 As the emerging field of oncofertility continues to 
grow, insurance companies will be faced with how to handle infertility 
for cancer patients. Amending the Massachusetts infertility mandate to 
include cancer patients is an equitable and cost-effective solution to a 
foreseeable harm from medically necessary treatment. This 
amendment to the mandate not only symbolizes the importance of 
fertility preservation treatment and the severity of infertility as a 
disease, but also opens the door for more discussions between patients 
and providers about fertility preservation treatment. Further, the 
amendment would improve a patient’s quality of life, and create a 
sense of fairness, consistency, and equality that is currently lost. 
The success rates for infertility treatments continue to improve, 
and a more expansive insurance coverage is likely to lead to more 
effective treatments while lowering the risks of infertility associated 
with cancer. For an individual or a couple who receives news of 
possible infertility, it can be devastating. Indeed, there is a dark irony 
in the fact that medical technology exists to enable them to have a 
child, but health insurance does not provide coverage for them. 
Although Massachusetts provides infertility coverage to the general 
public, it is simply not enough, as it excludes cancer patients. The 
amendment to the mandate would include a tragically excluded 
population while keeping costs low. Most importantly, the amended 
mandate would enable cancer patients to fulfill one of the most basic 
and beloved human desires: creating a family. 
After going through cancer and divorce battles, Maria now lives 
alone and constantly contemplates what life would be like if she never 
had cancer. She now lives in a society which indicated in every 
possible way that she was a broken woman, with thin hair and cracked 
eyebrows, with not a lash left on her eye. Her therapist suggested 
writing her thoughts down, and she decided to try, for she had nothing 
left to lose. 
She sits on her porch, with great wounds, beginning to scratch in a 
notebook. The moon was about in the same position it was always in, 
and provided enough light on her notebook to write. With tired hands 
and wet eyes, she picked up a pen and began to write: “At twenty-eight 
years old, I found out that cancer took my ability to have children too.” 
 
                                                            
164 See Niemasik, supra note 54, at S122. 
